FTRE vs GANX

Fortrea Holdings Inc. vs Gain Therapeutics, Inc. — Valuation Comparison 2026

FTRE

Biotechnology
Fortrea Holdings Inc.
Quality
5.3
out of 10
Value Trap
27
LOW
Price
$15.00
Last close
Models
9/13
Active
VS

GANX

Biotechnology
Gain Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
32
LOW
Price
$2.02
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType FTRE Fair ValueFTRE Upside GANX Fair ValueGANX Upside
Bayesian DCF Intrinsic $0.17 -98.8% $0.75 -63.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $12.15 -19.0% $0.47 -76.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for FTRE vs GANX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FTRE vs GANX — Which Stock Is More Undervalued?

FTRE scores higher with a 5.3/10 quality rating vs GANX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Fortrea Holdings Inc. (FTRE) and Gain Therapeutics, Inc. (GANX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FTRE currently trades at $15.00 with a QOC of 5.3/10, while GANX trades at $2.02 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).